China M&A Management Holdings, Inc. Acquires 4.93% Of China Pharmaceuticals International Corporation

HONG KONG, March 8 /Xinhua-PRNewswire/ -- China Pharmaceuticals International Corporation , announced today the Company received notification from China M&A Management Holdings, Inc. ("CMA"), confirming purchases of 3,929,450 shares from the market, which is 4.93% of the Company's outstanding shares for US$0.15 per share.

Founded in 1997, CMA is a financial services company focusing on domestic and cross-border mergers and acquisitions. It also provides M&A related restructuring, corporate finance, corporate governance and IPO advisory services to its clients. CMA has over 30 professionals operating in four of China's most dynamic cities: Peking, Shanghai, Suzhou and Shenyang.

Globalization has dramatically increased the number of cross-border M&A transactions over the past decade and WTO accession has opened China's market further to foreign corporations seeking to grow their business in Asia's fast- growing economy. The demand for M&A advisory services focusing on the China's market is rising dramatically in the anticipation of greatly increased business opportunities. With high recognition, CMA has strategically internationalized our services based on the concrete achievement of previous years.

CMA's dedicated specialists provide its clients the most innovative and customized M&A, financial and corporate restructuring solutions coupled with the latest news, research and analysis on the Chinese M&A market. CMA always works closely with our clients, listed or unlisted, state-owned or private enterprises, to meet their individual needs and to fit the unique Chinese marketplace.

Contact: China Pharmaceuticals International Corporation Sifie Fu, Investor Relations Manager Tel: +852-2255-0688 Email: sifiefu@DiChain.com Investor Relations Email: Investors@DiChain.com Website: http://www.chinapharmacorp.com/

China Pharmaceuticals International Corporation

CONTACT: Sifie Fu, Investor Relations Manager of China PharmaceuticalsInternational Corporation, +852-2255-0688, sifiefu@DiChain.com, InvestorRelations - Investors@DiChain.com

Back to news